Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

By J. Kochenderfer, M. Dudley, Sadik H. Kassim, R. Somerville, R. O. Carpenter, M. Stetler-Stevenson, Jie Yang, G. Phan, M. Hughes, R. Sherry and 16 more. Journal of Clinical Oncology, 2015

1,473 citations recorded by the source corpus.

Subfields: Dermatology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/647cbcaedc3f2229369cae50c4296ddab6368e2b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Dermatology

1. Hinrich Abken
2. M. Chmielewski

In Oncology

1. J. Kochenderfer
2. Jennifer N. Brudno

In Pathology and Forensic Medicine

1. Hinrich Abken
2. M. Chmielewski

Citations in the corpus

• B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. (2019, background): “org Volume 129 Number 6 June 2019 Neurotoxicity has been reported in up to 50% of subjects in some CAR T cell trials (13, 30, 31), can occur concurrently with or subsequent to CRS, often does not improve with tocilizumab, and is reversible in most, but not all, cases.”
• CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. (2016, neutral): “T cells and their subsequent expansion can be associated with cytokine release syndrome (CRS), characterized by hyperpyrexia, hypotension, capillary leak, neurotoxicity, and death in severe cases (3, 4, 7, 9, 10).”
• Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma (2017, neutral): “Hemorrhage intracranial 1 (14) 0 0 1 (14)”
• TRUCKs: the fourth generation of CARs (2015, background): “T cells engineered with such CARs targeting CD19 showed safety and robust clinical efficacy in the treatment of adult and childhood CD19 acute B-cell lymphoblastic leukemia in independent trials [16-19].”
• Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo (2015, neutral): “Comparing efficacy and toxicity outcomes in different studies is difficult because of patient heterogeneity and differences in vector design, culture methods, and cell doses 3–10,35,44 .”
• Toxicities of chimeric antigen receptor T cells: recognition and management. (2016, neutral): “If the tumorassociated antigen towhich theCAR is targeted is expressed on normal tissues, those tissuesmaybedamaged, as is the casewithnormalB cells being depleted by anti-CD19 CAR T cells.8,16,31 CAR T cells may damage normal tissues by unexpectedly cross-reacting with a protein that is not express”
• FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome (2018, background): “However, some authors noted cases of CRS refractory to tocilizumab therapy [13, 18].”